ACHV: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-39,986	-25,545
Depreciation and amortization note 3	171	117
Stock-based compensation note 7, note 7 and note 7	7,460	5,120
Amortization of 2024 svb convertible term loan transaction costs note 6	41	28
Change in fair value of contingent consideration note 4 and note 5	294	188
Prepaid expenses and other assets	-136	-592
Accounts payable	-7	-732
Accrued liabilities other	1,229	646
Accrued clinical liabilities	-227	893
Accrued compensation	-598	-1,464
Lease obligation note 9	1	-
Net cash used in operating activities	-31,488	-20,157
Proceeds from exercise of warrants	120	-
Proceeds from public offering, net of issuance costs-June2025Public Offering	41,140	41,222
Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 7b-June2025Public Offering	4,004	-
Net cash provided by financing activities	45,264	41,222
Purchase of marketable securities	19,664	4,260
Maturities of marketable securities	25,066	22,316
Net cash provided by (used in) investing activities	5,402	18,056
Effect of exchange rate changes on cash	-1	-
Net increase/(decrease) in cash, cash equivalents and restricted cash	19,177	39,121
Cash and cash equivalents at beginning of period	12,773	-
Cash and cash equivalents at end of period	31,950	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

ACHV: the cashflow